公开(公告)号：US20240207364A1

公开(公告)日：2024-06-27

申请号：US18426412

申请日：2024-01-30

申请人： Novo Nordisk A/S

发明人： Sarah Friedrich ,  Charlotte Christine Thim Hansen ,  Lotte Bjerre Knudsen ,  Anna Secher

IPC分类号： A61K38/26 ,  A61K9/20 ,  A61P25/28

CPC分类号： A61K38/26 ,  A61K9/2013 ,  A61P25/28

摘要： The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.

公开(公告)号：US11753455B2

公开(公告)日：2023-09-12

申请号：US17253708

申请日：2019-06-20

申请人： Novo Nordisk A/S

发明人： Nikolaj Kulahin Roed ,  Michael Paolo Bastner Sandrini ,  Jesper Lau ,  Paw Bloch ,  Anna Secher ,  Adam Paul Chambers ,  Jim McGuire ,  Lotte Bjerre Knudsen

IPC分类号： C07K14/575 ,  A61K47/62 ,  A61K38/00

CPC分类号： C07K14/575 ,  A61K47/62 ,  A61K38/00 ,  C07K2319/74

摘要： The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.

公开(公告)号：US20230302094A1

公开(公告)日：2023-09-28

申请号：US18208485

申请日：2023-06-12

申请人： Novo Nordisk A/S

发明人： Sarah Friedrich ,  Charlotte Christine Thim Hansen ,  Lotte Bjerre Knudsen ,  Anna Secher

IPC分类号： A61K38/26 ,  A61P25/28 ,  A61K9/20

CPC分类号： A61K38/26 ,  A61P25/28 ,  A61K9/2013

摘要： The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.

公开(公告)号：US20220280612A1

公开(公告)日：2022-09-08

申请号：US17736116

申请日：2022-05-04

申请人： Novo Nordisk A/S

发明人： Sarah Friedrich ,  Charlotte Christine Thim Hansen ,  Lotte Bjerre Knudsen ,  Anna Secher

IPC分类号： A61K38/26 ,  A61K9/20 ,  A61P25/28

摘要： The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.

公开(公告)号：US20210261641A1

公开(公告)日：2021-08-26

申请号：US17253708

申请日：2019-06-20

申请人： Novo Nordisk A/S

发明人： Nikolaj Kulahin Roed ,  Michael Paolo Bastner Sandrini ,  Jesper Lau ,  Paw Bloch ,  Anna Secher ,  Adam Paul Chambers ,  Jim McGuire ,  Lotte Bjerre Knudsen

IPC分类号： C07K14/575 ,  A61K47/62

摘要： The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.